EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Real‐world outcomes of low‐dose atropine therapy on myopia progression in an Australian cohort during the COVID ‐19 pandemic

Eiman Usmani iD, Stephanie Callisto, Weng Onn Chan, Deepa Taranath

Clinical & Experimental Ophthalmology · 2023

DOI: 10.1111/ceo.14289 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical & Experimental Ophthalmology, 2023. Verfasst von Eiman Usmani und 3 weiteren Autor:innen. Beteiligte Einrichtung: Discipline of Ophthalmology and Visual Science, University of Adelaide, Adelaide, South Australia, Australia. Hauptthemen laut MEDLINE: COVID-19, Myopia. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

To report the outcomes of low‐dose atropine (0.01% and 0.05%) for preventing myopia progression in a real‐world Australian cohort during the COVID‐19 pandemic.

Methods

Records of children presenting with myopia, from January 2016 to 2022, were retrospectively reviewed at a comprehensive ophthalmic practice. Children who discontinued treatment, ages >18, and cases with hereditary conditions were excluded. The rate of progression of myopia after treatment with atropine was compared with historical data to evaluate the effectiveness of the regime.

Results

One hundred and one children (mean baseline spherical equivalent [SphE] [−3.70 +/− 2.09 D] and axial length [AL] [24.59 +/− 1.00 mm]) were analysed. The mean age of the children was 10.4 +/− 2.89 years and 61% were females. The average follow‐up time was 17.9 +/− 12.5 months. The mean rate of progression of AL and SphE on 0.01% atropine eyedrops was 0.219 +/− 0.35 mm and − 0.250 +/− 0.86 D/year, respectively. 68.1% of the children treated with 0.01% atropine were mild progressors (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19MyopiaChildFemaleHumansAdolescentMaleAtropineRetrospective StudiesPandemicsAustraliaRefraction, OcularOphthalmic SolutionsAxial Length, EyeDisease ProgressionMydriatics

Stichwörter der Autor:innen

AustraliaCOVID-19low dose atropinemyopiareal-world outcomes

Substanzen

AtropineOphthalmic SolutionsMydriatics

Autor:innen und Institutionen

  • Discipline of Ophthalmology and Visual Science, University of Adelaide, Adelaide, South Australia, Australia.
  • Department of Ophthalmology, Royal Adelaide Hospital and South Australian Institute of Ophthalmology, Adelaide, South Australia, Australia.
  • Department of Ophthalmology, Flinders Medical Centre, Adelaide, South Australia, Australia.

ORCID-Profile: Eiman Usmani

Zitieren

APA

Usmani, E., Callisto, S., Chan, W. O., & Taranath, D. (2023). Real‐world outcomes of low‐dose atropine therapy on myopia progression in an Australian cohort during the COVID ‐19 pandemic. Clinical & Experimental Ophthalmology. https://doi.org/10.1111/ceo.14289

Vancouver

Usmani E, Callisto S, Chan WO, Taranath D. Real‐world outcomes of low‐dose atropine therapy on myopia progression in an Australian cohort during the COVID ‐19 pandemic. Clinical & Experimental Ophthalmology. 2023. doi:10.1111/ceo.14289

BibTeX
@article{Usmani2023,
  author = {Usmani, Eiman and Callisto, Stephanie and Chan, Weng Onn and Taranath, Deepa},
  title = {Real‐world outcomes of low‐dose atropine therapy on myopia progression in an Australian cohort during the COVID ‐19 pandemic},
  journal = {Clinical & Experimental Ophthalmology},
  year = {2023},
  doi = {10.1111/ceo.14289}
}
Kostenlos starten →